HIV/AIDS. Report of novel treatment aimed at latent HIV raises the 'c word'.
Cohen
Jon
J
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000821:virology*; D000077560:Enfuvirtide; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006678:HIV / Q000187:drug effects* / Q000502:physiology; D015700:HIV Envelope Protein gp41 / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology*; D056284:Histone Deacetylase 1; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D010446:Peptide Fragments / Q000627:therapeutic use; D014635:Valproic Acid / Q000627:therapeutic use*; D017735:Virus Latency / Q000187:drug effects*
D019380:Anti-HIV Agents; D004791:Enzyme Inhibitors; D015700:HIV Envelope Protein gp41; D056572:Histone Deacetylase Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide; D014635:Valproic Acid; C110550:HDAC1 protein, human; D056284:Histone Deacetylase 1